Pancreaticoduodenectomy and metastasectomy for metastatic pancreatic neuroendocrine tumors

• Published in: Journal of surgical oncology Vol. 118; no. 6; pp. 983 - 990
• Main Authors: Chawla, Akhil, Williams, Richelle T., Sich, Nicholas, Clancy, Thomas, Wang, Jiping, Ashley, Stanley, Pezzi, Christopher, Swanson, Richard
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.11.2018
• Subjects: Cancer surgery; metastasectomy; Metastasis; metastatic pancreatic neuroendocrine tumor; Neuroendocrine tumors; Pancreatic cancer; pancreatic neuroendocrine tumor (PNET); pancreaticoduodenectomy (PD); pancreatic neuroendocrine tumor (PNET); metastatic pancreatic neuroendocrine tumor; metastasectomy; pancreaticoduodenectomy (PD)
• ISSN: 0022-4790; 1096-9098
• DOI: 10.1002/jso.25219

Background and Objectives Various treatment options exist for patients with metastatic pancreatic neuroendocrine tumors (PNETs). Surgical resection with pancreaticoduodenectomy (PD) typically reserved for patients with limited disease. Definitive data are lacking to support either the resection of primary PNET in the metastatic setting or for surgical debulking of metastatic lesions. Methods We conducted an analysis of the National Cancer Database (NCDB) using the pancreatic cancer Participant User File. Thirty‐ and 90‐day mortality rates and survival rates were determined for patients undergoing PD for primary tumor resection and compared with patients who had no surgery or metastasectomy. The Kaplan‐Meier method was used to compare survival time. Cox regression models were used to assess factors independently associated with overall survival time. Results Resection of the primary tumor or metastatic disease each significantly improved overall survival time compared with no resection. Adding metastasectomy to PD resulted in an incremental increase in overall survival time. Both PD and metastasectomy are independently associated with overall survival time. Conclusions Our report highlights the potential for survival time benefit in appropriately selected patients who undergo PD in the setting of metastatic PNET.